JP2015505299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505299A5 JP2015505299A5 JP2014540570A JP2014540570A JP2015505299A5 JP 2015505299 A5 JP2015505299 A5 JP 2015505299A5 JP 2014540570 A JP2014540570 A JP 2014540570A JP 2014540570 A JP2014540570 A JP 2014540570A JP 2015505299 A5 JP2015505299 A5 JP 2015505299A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- vlp
- polypeptide
- pharmaceutical composition
- found
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 26
- 102000004169 proteins and genes Human genes 0.000 claims 26
- 229920001184 polypeptide Polymers 0.000 claims 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 239000013598 vector Substances 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 102000040430 polynucleotide Human genes 0.000 claims 15
- 108091033319 polynucleotide Proteins 0.000 claims 15
- 239000002157 polynucleotide Substances 0.000 claims 15
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 14
- 241000714177 Murine leukemia virus Species 0.000 claims 11
- 101710177291 Gag polyprotein Proteins 0.000 claims 9
- 101710125418 Major capsid protein Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 7
- 239000002671 adjuvant Substances 0.000 claims 7
- 230000001086 cytosolic effect Effects 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 5
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 238000011144 upstream manufacturing Methods 0.000 claims 4
- 102000003886 Glycoproteins Human genes 0.000 claims 3
- 108090000288 Glycoproteins Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 230000008488 polyadenylation Effects 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558800P | 2011-11-11 | 2011-11-11 | |
| US61/558,800 | 2011-11-11 | ||
| US201261654157P | 2012-06-01 | 2012-06-01 | |
| US61/654,157 | 2012-06-01 | ||
| PCT/IB2012/002854 WO2013068847A2 (en) | 2011-11-11 | 2012-11-09 | Compositions and methods for treatment of cytomegalovirus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017151540A Division JP6657150B2 (ja) | 2011-11-11 | 2017-08-04 | サイトメガロウイルスの治療のための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505299A JP2015505299A (ja) | 2015-02-19 |
| JP2015505299A5 true JP2015505299A5 (enExample) | 2016-01-07 |
| JP6232544B2 JP6232544B2 (ja) | 2017-11-22 |
Family
ID=48290708
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540570A Active JP6232544B2 (ja) | 2011-11-11 | 2012-11-09 | サイトメガロウイルスの治療のための組成物及び方法 |
| JP2017151540A Active JP6657150B2 (ja) | 2011-11-11 | 2017-08-04 | サイトメガロウイルスの治療のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017151540A Active JP6657150B2 (ja) | 2011-11-11 | 2017-08-04 | サイトメガロウイルスの治療のための組成物及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9777043B2 (enExample) |
| EP (2) | EP2776567B1 (enExample) |
| JP (2) | JP6232544B2 (enExample) |
| KR (2) | KR102301463B1 (enExample) |
| CN (3) | CN111995664B (enExample) |
| AU (3) | AU2012335277B2 (enExample) |
| BR (2) | BR112014011229B1 (enExample) |
| CA (2) | CA2889659C (enExample) |
| DK (1) | DK2776567T3 (enExample) |
| ES (1) | ES2874233T3 (enExample) |
| MX (2) | MX353189B (enExample) |
| PT (1) | PT2776567T (enExample) |
| RU (2) | RU2737530C1 (enExample) |
| WO (1) | WO2013068847A2 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3330368B1 (en) | 2009-06-18 | 2021-07-21 | Kiyatec Inc. | Bioreactor system |
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| EP4108671B1 (en) | 2010-10-01 | 2024-11-20 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PL3682905T3 (pl) | 2011-10-03 | 2022-04-04 | Modernatx, Inc. | Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania |
| WO2013068847A2 (en) | 2011-11-11 | 2013-05-16 | Variation Biotechnologies, Inc. | Compositions and methods for treatment of cytomegalovirus |
| PL2791160T3 (pl) | 2011-12-16 | 2022-06-20 | Modernatx, Inc. | Kompozycje zmodyfikowanego mrna |
| JP6265344B2 (ja) * | 2012-03-27 | 2018-01-24 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | 抗サイトメガロウイルス中和抗体の検出方法 |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| JP6294890B2 (ja) * | 2012-10-30 | 2018-03-14 | ファイザー・インク | ヒトサイトメガロウイルス感染に対する組換え粒子ベースのワクチン |
| RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| WO2015193143A1 (en) | 2014-06-18 | 2015-12-23 | Morphosys Ag | Fusion proteins and uses thereof |
| KR101678740B1 (ko) * | 2014-10-24 | 2016-11-23 | 단국대학교 천안캠퍼스 산학협력단 | 세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질 |
| WO2016149426A1 (en) * | 2015-03-16 | 2016-09-22 | The Broad Institute, Inc. | Constructs for continuous monitoring of live cells |
| US10968253B2 (en) | 2015-10-20 | 2021-04-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and products for genetic engineering |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| WO2018165631A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| WO2019209632A1 (en) * | 2018-04-24 | 2019-10-31 | Merck Sharp & Dohme Corp. | Scalable chromatography process for purification of human cytomegalovirus |
| CA3099381A1 (en) | 2018-05-04 | 2019-11-07 | SpyBiotech Limited | Vaccine composition |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CA3130488A1 (en) | 2019-03-19 | 2020-09-24 | David R. Liu | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US20200376113A1 (en) * | 2019-05-31 | 2020-12-03 | Variation Biotechnologies Inc. | Immunotherapeutic compositions for treatment of glioblastoma multiforme |
| US20220259617A1 (en) | 2019-06-13 | 2022-08-18 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| GB201910651D0 (en) * | 2019-07-25 | 2019-09-11 | Autolus Ltd | Virus-like particle |
| EP4028051A1 (en) * | 2019-09-09 | 2022-07-20 | GlaxoSmithKline Biologicals S.A. | Immunotherapeutic compositions |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| MX2023001028A (es) | 2020-07-24 | 2023-04-24 | Massachusetts Gen Hospital | Particulas similares a virus potenciadas y metodos de uso de las mismas para suministro a celulas. |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN115948468A (zh) * | 2022-09-09 | 2023-04-11 | 青岛大学 | 一种人巨细胞病毒重组载体及其制备方法和应用 |
| WO2024243675A1 (en) * | 2023-06-02 | 2024-12-05 | Variation Biotechnologies Inc. | Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267965B1 (en) | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
| JPS61103895A (ja) * | 1984-10-26 | 1986-05-22 | Green Cross Corp:The | ＨＢｓＡｇの精製方法 |
| EP0436537A4 (en) * | 1988-01-29 | 1992-04-08 | Chiron Corporation | Recombinant cmv neutralizing proteins |
| US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
| DE19856463B4 (de) * | 1998-11-26 | 2006-02-02 | Heinrich-Pette-Institut | Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren |
| DE19910044A1 (de) | 1999-03-08 | 2000-09-14 | Bodo Plachter | Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff |
| ATE345389T1 (de) * | 1999-09-30 | 2006-12-15 | Univ Washington | Immunologisch relevante antigene aus herpes simplexvirus |
| EP1201750A1 (en) * | 2000-10-26 | 2002-05-02 | Genopoietic | Synthetic viruses and uses thereof |
| US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| CA2756797C (en) | 2002-12-23 | 2015-05-05 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| PT1651666E (pt) | 2003-07-11 | 2009-08-28 | Alphavax Inc | Vacinas de citomegalovírus à base de alfavírus |
| RU2290204C1 (ru) * | 2005-07-27 | 2006-12-27 | Общество с ограниченной ответственностью "Аванген" | Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани |
| EP2044224A4 (en) * | 2006-07-27 | 2011-04-13 | Ligocyte Pharmaceuticals Inc | CHIMERIC VIRUS TYPE PARTICLES |
| US20090123494A1 (en) * | 2007-07-31 | 2009-05-14 | William Staplin | Momlv-based pseudovirion packaging cell line |
| US20110250675A1 (en) | 2008-03-26 | 2011-10-13 | Life Technologies Corporaiton | Virus-Like Particle Mediated Cellular Delivery |
| GB0907935D0 (en) * | 2009-05-08 | 2009-06-24 | Henderson Morley Plc | Vaccines |
| WO2013068847A2 (en) | 2011-11-11 | 2013-05-16 | Variation Biotechnologies, Inc. | Compositions and methods for treatment of cytomegalovirus |
| JP6679484B2 (ja) | 2013-12-11 | 2020-04-15 | ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | ヒトヘルペスウイルス三量体糖タンパク質Ｂ、三量体ｇＢを含むタンパク質複合体、及びワクチンとしてのそれらの使用 |
-
2012
- 2012-11-09 WO PCT/IB2012/002854 patent/WO2013068847A2/en not_active Ceased
- 2012-11-09 CN CN202010272504.4A patent/CN111995664B/zh active Active
- 2012-11-09 US US14/357,423 patent/US9777043B2/en active Active
- 2012-11-09 ES ES12847559T patent/ES2874233T3/es active Active
- 2012-11-09 KR KR1020147015909A patent/KR102301463B1/ko active Active
- 2012-11-09 EP EP12847559.7A patent/EP2776567B1/en active Active
- 2012-11-09 BR BR112014011229-0A patent/BR112014011229B1/pt active IP Right Grant
- 2012-11-09 PT PT128475597T patent/PT2776567T/pt unknown
- 2012-11-09 CA CA2889659A patent/CA2889659C/en active Active
- 2012-11-09 JP JP2014540570A patent/JP6232544B2/ja active Active
- 2012-11-09 CA CA3166278A patent/CA3166278A1/en active Pending
- 2012-11-09 MX MX2014005653A patent/MX353189B/es active IP Right Grant
- 2012-11-09 RU RU2014123465A patent/RU2737530C1/ru active
- 2012-11-09 CN CN201711042348.7A patent/CN107875382B/zh active Active
- 2012-11-09 KR KR1020197025818A patent/KR102340558B1/ko active Active
- 2012-11-09 AU AU2012335277A patent/AU2012335277B2/en active Active
- 2012-11-09 DK DK12847559.7T patent/DK2776567T3/da active
- 2012-11-09 MX MX2017017128A patent/MX387666B/es unknown
- 2012-11-09 CN CN201280066355.XA patent/CN104271745A/zh active Pending
- 2012-11-09 EP EP21152309.7A patent/EP3854416A1/en active Pending
- 2012-11-09 BR BR122019027913-6A patent/BR122019027913B1/pt active IP Right Grant
- 2012-11-09 RU RU2019139064A patent/RU2019139064A/ru unknown
-
2017
- 2017-08-04 JP JP2017151540A patent/JP6657150B2/ja active Active
- 2017-08-22 US US15/683,355 patent/US11248026B2/en active Active
-
2018
- 2018-05-18 AU AU2018203538A patent/AU2018203538A1/en not_active Abandoned
-
2020
- 2020-11-03 AU AU2020264275A patent/AU2020264275B2/en active Active
-
2022
- 2022-02-11 US US17/670,052 patent/US12421283B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505299A5 (enExample) | ||
| CN111939250B (zh) | 一种预防covid-19的疫苗及其制备方法 | |
| RU2019139064A (ru) | Композиции и способы для лечения цитомегаловируса | |
| WO2021189571A1 (zh) | 一种高效诱导机体体液免疫应答的疫苗载体、其制备方法及用途 | |
| JP2009544318A5 (enExample) | ||
| JP2019514373A5 (enExample) | ||
| FI3972987T3 (fi) | Antigeenispesifinen immunoterapia COVID-19-fuusioproteiineille ja sen käyttömenetelmät | |
| JP2014530010A5 (enExample) | ||
| WO2018176103A1 (en) | "chimeric molecules and uses thereof" | |
| RU2015155821A (ru) | Вакцины против малярии | |
| Jiang et al. | Hantavirus Gc induces long-term immune protection via LAMP-targeting DNA vaccine strategy | |
| RU2014117068A (ru) | Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса | |
| CN104271594A (zh) | 用于初免-加强疫苗的水疱性口炎病毒 | |
| JP2019512251A5 (enExample) | ||
| TW202130363A (zh) | 變異型ｒｓｖ ｆ蛋白質及其利用 | |
| JP2018524019A5 (enExample) | ||
| WO2019092002A1 (en) | Pharmaceutical compositions for treatment or prevention of viral infections | |
| TW202227126A (zh) | 異源初免加強疫苗 | |
| CN107254447B (zh) | Anti AFP CAR-T细胞及其制备方法和应用 | |
| JP2017538443A5 (enExample) | ||
| AU2021333793A1 (en) | Immunogenic coronavirus fusion proteins and related methods | |
| JP2010538619A5 (enExample) | ||
| JP2026500600A (ja) | Ｈｐｖ感染関連疾患を予防又は治療するためのポリヌクレオチド分子 | |
| CN117003856B (zh) | 一种靶向乙肝表面抗原的t细胞受体工程化t细胞 | |
| CA3116623A1 (en) | Fusion protein |